Have a feature idea you'd love to see implemented?
Let us know!
ANVS Annovis Bio Inc
Price (delayed)
$9.24
Market cap
$120.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.5
Enterprise value
$116.62M
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS).
Highlights
ANVS's equity has dropped by 108% year-on-year but it is up by 48% since the previous quarter
The quick ratio has dropped by 87% year-on-year but it has soared by 55% since the previous quarter
Key stats
What are the main financial stats of ANVS
Market
Valuations
Earnings
Shares outstanding
13.05M
Market cap
$120.62M
Enterprise value
$116.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$43.02M
EBITDA
-$43.02M
Free cash flow
-$29.14M
Per share
Balance sheet
Liquidity
EPS
-$4.5
Free cash flow per share
-$2.58
Book value per share
-$0.16
Revenue per share
$0
TBVPS
$0.45
Total assets
$5.05M
Total liabilities
$6.8M
Debt
$0
Equity
-$1.75M
Working capital
$989,116
Debt to equity
0
Current ratio
1.24
Quick ratio
0.99
Net debt/EBITDA
0.09
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-516.9%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-4,349.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANVS stock price
How has the Annovis Bio stock price performed over time
Intraday
-4.05%
1 week
1.09%
1 month
15.5%
1 year
16.37%
YTD
-50.59%
QTD
14.64%
Financial performance
How have Annovis Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$40.88M
Net income
-$43.02M
Gross margin
N/A
Net margin
N/A
The net income is down by 29% year-on-year but it is up by 10% since the previous quarter
The company's operating income fell by 20% YoY but it rose by 4.7% QoQ
Growth
What is Annovis Bio's growth rate over time
Valuation
What is Annovis Bio stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 13% year-on-year but it has grown by 12% since the previous quarter
ANVS's equity has dropped by 108% year-on-year but it is up by 48% since the previous quarter
Efficiency
How efficient is Annovis Bio business performance
The return on assets has declined by 39% since the previous quarter
Dividends
What is ANVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANVS.
Financial health
How did Annovis Bio financials performed over time
Annovis Bio's total assets is 26% lower than its total liabilities
ANVS's current ratio has plunged by 89% YoY and by 23% from the previous quarter
The quick ratio has dropped by 87% year-on-year but it has soared by 55% since the previous quarter
The company's debt is 100% higher than its equity
ANVS's equity has dropped by 108% year-on-year but it is up by 48% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.